Summary of Key Points Core Viewpoint - The company has decided to cancel a previously approved guarantee of up to 50 million RMB for its subsidiary, which will help in better managing financing guarantees without negatively impacting its operations or long-term interests [1][2]. Group 1: Guarantee Situation Overview - The company approved a financing credit of up to 50 million RMB for its subsidiary, with a joint liability guarantee provided by another subsidiary [1]. - The guarantee was related to a loan application made by Beijing Huasu Pharmaceutical Co., Ltd. to Beijing Bank [1]. Group 2: Cancellation of Guarantee - The cancellation of the 50 million RMB guarantee is aimed at effectively managing the external guarantee limits and aligning with the funding needs of the company and its subsidiaries [2]. - The cancellation will not adversely affect the company's normal operations or business development [2]. Group 3: Total Guarantee Amount and Status - After the cancellation, the total guarantee amount for the company and its subsidiaries stands at 896 million RMB, which is 56.41% of the latest audited net assets and 24.14% of total assets [3]. - The total balance of external guarantees is 552.38 million RMB, accounting for 34.78% of the latest audited net assets, with no overdue guarantees or litigation issues reported [3].

Group 1 - The company held the 15th meeting of the 10th Supervisory Board on June 13, 2025, with all three supervisors participating in the voting, which complied with relevant regulations [2][4] - The Supervisory Board approved the financial write-off of asset losses, with a total original value of inventory and fixed assets amounting to 1,789,961.56 yuan and an estimated loss of 978,888.18 yuan, impacting the total profit for 2024 by 825,135.58 yuan [3][4] - The financial write-off will not affect the company's profit and loss for the year 2025, as the impact has already been accounted for in previous years [3] Group 2 - The company announced the proposed cancellation of its subsidiary, Guangxi Wuzhou Zhongheng Pharmaceutical (Hong Kong) Co., Ltd., during the 29th meeting of the 10th Board of Directors held on June 13, 2025 [7][12] - The reason for the cancellation is that the subsidiary has not engaged in substantial operations since its establishment, and the company aims to optimize its organizational structure and improve operational efficiency [8] - The cancellation will not involve personnel arrangements and is not expected to have a significant impact on the company's financial and operational status [9] Group 3 - The Board of Directors approved the establishment of the "Overseas Investment Management Measures" and the "Financing Guarantee Management Measures," as well as the revision of the "Financing Management System" [13][15][16] - All resolutions passed with unanimous support from the board members, indicating strong consensus on these governance measures [14][15]